Prognostic Value of Blasts in Peripheral Blood in Myelofibrosis in the Ruxolitinib Era

BACKGROUND: Peripheral blasts (PB) ≥1% have long been considered an unfavorable feature for patients with primary myelofibrosis (PMF). Whether further quantification of PB blasts and their correlation with bone marrow (BM) blasts has incremental value with regards to patient prognostication is uncle...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Masarova, Lucia, Bose, Prithviraj, Pemmaraju, Naveen, Daver, Naval G., Zhou, Lingsha, Pierce, Sherry, Sasaki, Koji, Kantarjian, Hagop, Estrov, Zeev, Verstovsek, Srdan
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7875207/
https://ncbi.nlm.nih.gov/pubmed/32697338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.33094
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados